Sort
48,018 grants matching “immunotherapy”
Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
$533,951Emily H Cheng · Sloan-Kettering Inst Can Research · U54 · FY2022 · CA
A deubiquitination module controls Treg adaptation to tumor microenvironment
$533,802Deyu Fang · Northwestern University At Chicago · R01 · FY2024 · CA
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
$533,791Robert J Gray · Dana-Farber Cancer Inst · U01 · FY2019 · CA
Adoptive Cell Therapies and Translational Neuroimaging in Synucleinopathy
$533,750Vinata Vedam-Mai · University Of Florida · R56 · FY2019 · NS
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction
$533,743Amy E Moran · Oregon Health & Science University · R37 · FY2023 · CA
Reprogramming the tumor microenvironment via self-amplified RNA (SafeR) circuits
$533,720Ron Weiss · Massachusetts Institute Of Technology · R01 · FY2019 · CA
Precision-based Assessment for the Detection of Mild Cognitive Impairment in Older Adults
$533,609Rosie E Curiel Cid · University Of Miami School Of Medicine · R01 · FY2020 · AG
SMALL ANIMAL MULTI-MODALITY IMAGING CENTER (SAMMIC)
$533,546University Of Pennsylvania · R24 · FY2000 · CA
Project 1: Costimulation and Regulation of Anti-viral Immunity
$533,498Arlene H Sharpe · Harvard Medical School · P01 · FY2016 · AI
Mechanisms of Murine Tumor Eradication by Immunotherapy
$533,495Philip D Greenberg · University Of Washington · R01 · FY2011 · CA
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC
$533,483Xiao-Jing Wang · University Of Colorado Denver · R01 · FY2021 · DE
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC
$533,483Xiao-Jing Wang · University Of Colorado Denver · R01 · FY2019 · DE
Mechanisms of dual inhibition of TGFbeta/PD-L1 in HNSCC
$533,483Xiao-Jing Wang · University Of Colorado Denver · R01 · FY2020 · DE
Controllable In Vivo Genome Editing for Immune-Checkpoint Blockade in Solid Tumors
$533,472Sheng Tong · Rice University · R01 · FY2018 · EB
Molecular Genetics
$533,439Carlo M Croce · University Of California, San Diego · P01 · FY2015 · CA
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$533,414Yaguang Xi · University Of Georgia · R01 · FY2024 · CA
Targeting posttranslational modifications of CD73 in TNBCs
$533,393Yong Wan · Emory University · R01 · FY2024 · CA
Macrophage-specific nanotherapy for breast cancer
$533,380Bryan Ronain Smith · Michigan State University · R01 · FY2025 · CA
Assessing Metabolically Reprogrammed and Purified CD19-CAR-T in NHL and CLL
$533,348Brian Hess · Medical University Of South Carolina · R01 · FY2024 · CA
IONIC MECHANISMS OF RESISTANCE TO IMMUNOTHERAPY IN HEAD AND NECK CANCER
$533,320Cincinnati Univ Of · · FY2017 · Department of the Army
Mechanism(s) of pathogenicity for Candida auris
$533,314Jeniel E Nett · University Of Wisconsin-Madison · R01 · FY2021 · AI
Group 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer Immunity
$533,314Vinod P Balachandran · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Role of IL-12 family cytokines in human autoimmune Uveitis
$533,284Charles E Egwuagu · National Eye Institute · ZIA · FY2018 · EY
Immunosurveillance and Immunopathology Core
$533,167Sabarinathan Ramachandran · University Of Minnesota · U19 · FY2024 · AI
Inhibition of Natural Killer Cell Function
$533,105Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI